Advertisement
ABOS vs PMN
Which Stock Would AI Choose? Acumen Pharmaceuticals (ABOS) vs. ProMIS Neurosciences (PMN) Stock Comparison
Key Takeaways
- Both ABOS and PMN are clinical-stage biotechs pursuing Alzheimer's disease treatments, but their recent fortunes have diverged sharply after ABOS discontinued its lead drug candidate.
- ABOS saw its shares collapse after its Phase 2 ALTITUDE-AD trial of sabirnetug failed to meet its primary endpoint, prompting multiple analyst downgrades and deep price-target cuts.
- PMN fell in a sympathy sell-off but retains an active lead program, PMN310, with unblinded data expected in early 2027.
- Relative market positioning now favors PMN, which still holds a defined near-term catalyst, versus ABOS, whose valuation has been reset around a much smaller cash runway.
- Tickeron AI Verdict: PMN is the favored ticker of the two based on the presence of an intact clinical catalyst and comparatively stronger risk-reward positioning.
- For more context, explore ABOS Major News and ABOS Today's Price Move, as well as PMN Major News and PMN Today's Price Move.
- To see how automated strategies are positioning across this and thousands of other tickers, visit Trending AI Robots.
Introduction
This stock comparison examines two small-cap, clinical-stage biotechnology companies pursuing similar science in Alzheimer's disease: Acumen Pharmaceuticals (ABOS) and ProMIS Neurosciences (PMN). Both target toxic amyloid-beta oligomers, and both carry the binary risk profile typical of pre-revenue drug developers. Their paths diverged dramatically in recent weeks, however, making the pairing a useful case study in how a single clinical event can reshape relative performance and market positioning. This comparison may be most relevant to event-driven traders and investors comfortable with elevated volatility in the speculative biotechnology segment.
ABOS Overview and Recent Performance
Acumen Pharmaceuticals (ABOS) is a clinical-stage biopharmaceutical company focused on Alzheimer's disease. Its lead asset, sabirnetug, was designed to selectively target toxic amyloid-beta oligomers. In recent market activity, the stock suffered a severe decline after initial top-line data from the Phase 2 ALTITUDE-AD trial showed sabirnetug did not meet its primary endpoint on cognitive and functional decline at either tested dose. The company subsequently announced plans to discontinue sabirnetug's development. Multiple Wall Street firms, including Citigroup, Stifel, BofA, and BTIG, responded with downgrades or sharp price-target reductions. Acumen ended its most recent quarter with cash and marketable securities of roughly $79 million, with management guiding that the balance sheet supports operations into early 2027. The failure removes the company's near-term value catalyst and leaves its Enhanced Brain Delivery program, with a mid-2027 investigational new drug (IND) filing target, as the primary remaining pipeline driver.
PMN Overview and Recent Performance
ProMIS Neurosciences (PMN) is a clinical-stage biotechnology company developing antibody therapeutics against toxic misfolded proteins. Its lead candidate, PMN310, is also designed to target amyloid-beta oligomers while avoiding plaque, with the goal of reducing amyloid-related imaging abnormalities (ARIA), a side effect linked to existing amyloid-targeting therapies. PMN shares declined roughly 70% in a sympathy sell-off following Acumen's trial failure, as investors questioned whether the oligomer-targeting approach itself might be flawed. Analysts, including Roth Capital, lowered price targets but maintained Buy ratings, arguing a one-for-one extrapolation is premature given differences in antibody design. ProMIS reported no cases of ARIA-E in an interim safety analysis of its Phase 1b PRECISE-AD trial, and unblinded 12-month results are expected in the first quarter of 2027. The company's cash is expected to fund operations through 2027.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI trading bots drawn from a broader library of hundreds of automated strategies that collectively trade thousands of tickers. Each bot operates with its own trading style, strategy, timeframe, performance history, and basket of tickers, so no two are identical. The bots featured in the Trending section are those considered best suited to current market conditions, offering traders a way to observe how quantitative, rules-based approaches are responding to shifting volatility and momentum across the market. For those tracking high-volatility names such as ABOS and PMN, these tools can provide an additional, data-driven perspective. Explore the Trending AI Robots page to review the strategies currently leading the rankings.
Head-to-Head Comparison
The two companies share a therapeutic thesis but now sit in very different market positions. ABOS has lost its lead clinical asset, leaving its near-term investment case tied to a smaller pipeline and a financing-sensitive balance sheet. PMN, by contrast, retains a live, fully enrolled Phase 1b program with a defined catalyst in early 2027. On growth drivers, PMN still has a pathway to proof-of-concept, while ABOS must pivot to earlier-stage work. On risk, both stocks remain highly speculative, but ABOS faces the added near-term concern of a thinning cash runway relative to its remaining milestones. Sector exposure is nearly identical, yet market sentiment has clearly differentiated the two: analyst actions on ABOS were broadly negative downgrades, whereas coverage on PMN retained Buy ratings with reduced targets.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely favor PMN over ABOS at this juncture. PMN retains an intact clinical catalyst, a more favorable safety signal so far, and analyst coverage that remains constructive despite reduced targets. ABOS, following the discontinuation of sabirnetug, carries a diminished near-term catalyst set and a comparatively constrained cash position. The verdict is probabilistic rather than definitive, reflecting the inherent uncertainty in early-stage biotechnology, but relative positioning, trend consistency, and catalyst availability currently point toward PMN.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABOS is a Hold and PMN is a Hold.
ABOS sees its 50-day moving average cross bearishly below its 200-day moving average
The 50-day moving average for ABOS moved below the 200-day moving average on October 26, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for ABOS turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 38 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABOS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for ABOS entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Momentum Indicator moved above the 0 level on November 13, 2026. You may want to consider a long position or call options on ABOS as a result. In 76 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
Following a +10.85% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABOS advanced for three days, in 208 of 248 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
ABOS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.282) is normal, around the industry mean (3.498). P/E Ratio (-0.136) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 99 (best 1 - 100 worst), indicating slightly worse than average price growth. ABOS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABOS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Momentum Indicator for PMN turns negative, indicating new downward trend
PMN saw its Momentum Indicator move below the 0 level on October 30, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 106 similar instances where the indicator turned negative. In 97 of the 106 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for PMN turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 49 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
The 50-day moving average for PMN moved below the 200-day moving average on October 13, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PMN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for PMN entered a downward trend on October 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for PMN's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +18.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where PMN advanced for three days, in 154 of 185 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
PMN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.755) is normal, around the industry mean (3.498). P/E Ratio (-0.330) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 96 (best 1 - 100 worst), indicating slightly worse than average price growth. PMN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PMN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
PMN | ||
|---|---|---|
OUTLOOK RATING 1..100 | 4 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 92 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 99 | |
PRICE GROWTH RATING 1..100 | 96 | |
P/E GROWTH RATING 1..100 | 7 | |
SEASONALITY SCORE 1..100 | 12 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| ABOS | PMN | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 86% | 2 days ago 83% |
| Momentum ODDS (%) | 2 days ago 80% | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 83% | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 87% | 2 days ago 90% |
| TrendMonth ODDS (%) | 2 days ago 83% | 2 days ago 90% |
| Advances ODDS (%) | 6 days ago 84% | 9 days ago 83% |
| Declines ODDS (%) | 2 days ago 87% | 2 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 88% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 87% | 2 days ago 87% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABOS’s FA Score shows that 1 FA rating(s) are green while PMN’s FA Score has 1 green FA rating(s).
- ABOS’s FA Score: 1 green, 4 red.
- PMN’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABOS’s TA Score shows that 5 TA indicator(s) are bullish while PMN’s TA Score has 4 bullish TA indicator(s).
- ABOS’s TA Score: 5 bullish, 4 bearish.
- PMN’s TA Score: 4 bullish, 5 bearish.
Price Growth
ABOS (@Biotechnology) experienced а -4.25% price change this week, while PMN (@Biotechnology) price change was -20.91% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -3.38%. For the same industry, the average monthly price growth was -5.88%, and the average quarterly price growth was -18.27%.
Reported Earning Dates
ABOS is expected to report earnings on Mar 29, 2027.
Industries' Descriptions
@Biotechnology (-3.38% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ABOS and
Correlation & Price change
A.I.dvisor indicates that over the last year, ABOS has been closely correlated with PMN. These tickers have moved in lockstep 76% of the time. This A.I.-generated data suggests there is a high statistical probability that if ABOS jumps, then PMN could also see price increases.
| Ticker / NAME | Correlation To ABOS | 1D Price Change % | ||
|---|---|---|---|---|
| ABOS | 100% | -1.83% | ||
| PMN - ABOS | 76% Closely correlated | -5.46% | ||
| PTHS - ABOS | 55% Loosely correlated | -7.35% | ||
| GYRE - ABOS | 54% Loosely correlated | +0.23% | ||
| CRMD - ABOS | 45% Loosely correlated | -3.72% | ||
| SANA - ABOS | 42% Loosely correlated | +0.50% | ||
More | ||||